# ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

> **NCT00048321** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 160 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** ISIS 104838

## Key facts

- **NCT ID:** NCT00048321
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01-01
- **Primary completion:** 2003-02-01
- **Final completion:** 2003-02-01
- **Target enrollment:** 160 (—)
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048321, "ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00048321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*